Suzhou BoomRay Chuanghe Pharmaceutical

BoomRay Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative radionuclide conjugated drugs (RDCs). The company utilizes its proprietary technology platforms to create targeted radiopharmaceuticals for both the diagnosis and treatment of various cancers, following a theranostic approach. Their lead program, BR-001, targets Fibroblast Activation Protein (FAP) and is currently in Phase 2 clinical trials for solid tumors. BoomRay's pipeline also includes candidates targeting Prostate-Specific Membrane Antigen (PSMA) and Somatostatin Receptors (SSTR). Backed by prominent investors such as Sequoia China and GL Capital, the company aims to provide precision medicine solutions for unmet needs in oncology.